476 related articles for article (PubMed ID: 26472278)
21. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3).
Edwards CJ; Blanco FJ; Crowley J; Birbara CA; Jaworski J; Aelion J; Stevens RM; Vessey A; Zhan X; Bird P
Ann Rheum Dis; 2016 Jun; 75(6):1065-73. PubMed ID: 26792812
[TBL] [Abstract][Full Text] [Related]
22. Apremilast for the management of moderate to severe plaque psoriasis.
Vangipuram R; Alikhan A
Expert Rev Clin Pharmacol; 2017 Apr; 10(4):349-360. PubMed ID: 28276777
[TBL] [Abstract][Full Text] [Related]
23. Apremilast increases IL-10-producing regulatory B cells and decreases proinflammatory T cells and innate cells in psoriatic arthritis and psoriasis.
Mavropoulos A; Zafiriou E; Simopoulou T; Brotis AG; Liaskos C; Roussaki-Schulze A; Katsiari CG; Bogdanos DP; Sakkas LI
Rheumatology (Oxford); 2019 Dec; 58(12):2240-2250. PubMed ID: 31209492
[TBL] [Abstract][Full Text] [Related]
24. Phosphodiesterase 4 Inhibitors in Immune-mediated Diseases: Mode of Action, Clinical Applications, Current and Future Perspectives.
Sakkas LI; Mavropoulos A; Bogdanos DP
Curr Med Chem; 2017; 24(28):3054-3067. PubMed ID: 28554321
[TBL] [Abstract][Full Text] [Related]
25. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor: A novel treatment option for nurse practitioners treating patients with psoriatic disease.
Young M; Roebuck HL
J Am Assoc Nurse Pract; 2016 Dec; 28(12):683-695. PubMed ID: 27869356
[TBL] [Abstract][Full Text] [Related]
26. A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial.
Cutolo M; Myerson GE; Fleischmann RM; Lioté F; Díaz-González F; Van den Bosch F; Marzo-Ortega H; Feist E; Shah K; Hu C; Stevens RM; Poder A
J Rheumatol; 2016 Sep; 43(9):1724-34. PubMed ID: 27422893
[TBL] [Abstract][Full Text] [Related]
27. Apremilast: first global approval.
Poole RM; Ballantyne AD
Drugs; 2014 May; 74(7):825-37. PubMed ID: 24797159
[TBL] [Abstract][Full Text] [Related]
28. Apremilast for the treatment of psoriasis.
Chimenti MS; Gramiccia T; Saraceno R; Bianchi L; Garofalo V; Buonomo O; Perricone R; Chimenti S; Chiricozzi A
Expert Opin Pharmacother; 2015; 16(13):2083-94. PubMed ID: 26243735
[TBL] [Abstract][Full Text] [Related]
29. Skin involvement in patients with psoriatic arthritis: preliminary results of treatment with apremilast in real world setting.
Radi G; Campanati A; Diotallevi F; Molinelli E; Offidani A
G Ital Dermatol Venereol; 2019 Apr; 154(2):166-169. PubMed ID: 30229640
[TBL] [Abstract][Full Text] [Related]
30. Real-world use of apremilast for patients with psoriasis in Japan.
Kishimoto M; Komine M; Hioki T; Kamiya K; Sugai J; Ohtsuki M
J Dermatol; 2018 Nov; 45(11):1345-1348. PubMed ID: 30168880
[TBL] [Abstract][Full Text] [Related]
31. Apremilast for the treatment of psoriatic arthritis.
Varada S; Tintle SJ; Gottlieb AB
Expert Rev Clin Pharmacol; 2014 May; 7(3):239-50. PubMed ID: 24702658
[TBL] [Abstract][Full Text] [Related]
32. Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic Arthritis.
Torres T; Puig L
Am J Clin Dermatol; 2018 Feb; 19(1):23-32. PubMed ID: 28597182
[TBL] [Abstract][Full Text] [Related]
33. Small molecule therapy for managing moderate to severe psoriatic arthritis.
Costa L; Del Puente A; Peluso R; Tasso M; Caso P; Chimenti MS; Sabbatino V; Girolimetto N; Benigno C; Bertolini N; Del Puente A; Perricone R; Scarpa R; Caso F
Expert Opin Pharmacother; 2017 Oct; 18(15):1557-1567. PubMed ID: 28891341
[TBL] [Abstract][Full Text] [Related]
34. Effect of the phosphodiesterase 4 inhibitor apremilast on cardiometabolic outcomes in psoriatic disease-results of the Immune Metabolic Associations in Psoriatic Arthritis study.
Ferguson LD; Cathcart S; Rimmer D; Semple G; Brooksbank K; Paterson C; Brown R; Harvie J; Gao X; Radjenovic A; Welsh P; McInnes IB; Sattar N; Siebert S
Rheumatology (Oxford); 2022 Mar; 61(3):1026-1034. PubMed ID: 34097014
[TBL] [Abstract][Full Text] [Related]
35. Novel Oral Therapies for Psoriasis and Psoriatic Arthritis.
Yiu ZZ; Warren RB
Am J Clin Dermatol; 2016 Jun; 17(3):191-200. PubMed ID: 26923915
[TBL] [Abstract][Full Text] [Related]
36. Apremilast for discoid lupus erythematosus: results of a phase 2, open-label, single-arm, pilot study.
De Souza A; Strober BE; Merola JF; Oliver S; Franks AG
J Drugs Dermatol; 2012 Oct; 11(10):1224-6. PubMed ID: 23134988
[TBL] [Abstract][Full Text] [Related]
37. [Gastrointestinal side effects of apremilast : Characterization and management].
Pinter A; Beigel F; Körber A; Homey B; Beissert S; Gerdes S; Staubach-Renz P; Radtke MA; Mössner R
Hautarzt; 2019 May; 70(5):354-362. PubMed ID: 30937481
[TBL] [Abstract][Full Text] [Related]
38. Effects of Apremilast on Pruritus and Skin Discomfort/Pain Correlate With Improvements in Quality of Life in Patients With Moderate to Severe Plaque Psoriasis.
Sobell JM; Foley P; Toth D; Mrowietz U; Girolomoni G; Goncalves J; Day RM; Chen R; Yosipovitch G
Acta Derm Venereol; 2016 May; 96(4):514-20. PubMed ID: 26837052
[TBL] [Abstract][Full Text] [Related]
39. Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis.
Bissonnette R; Pariser DM; Wasel NR; Goncalves J; Day RM; Chen R; Sebastian M
J Am Acad Dermatol; 2016 Jul; 75(1):99-105. PubMed ID: 27021239
[TBL] [Abstract][Full Text] [Related]
40. ▼ Apremilast for psoriasis and psoriatic arthritis.
Drug Ther Bull; 2015 Sep; 53(9):105-8. PubMed ID: 26358317
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
